Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 0.95 -1.56% -0.02
CYCC closed down 1.56 percent on Friday, March 22, 2019, on 1.17 times normal volume.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CYCC trend table...

Date Alert Name Type % Chg
Mar 22 Calm After Storm Range Contraction 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Volume Surge Other -1.56%
Mar 21 Upper Bollinger Band Walk Strength -1.56%
Mar 21 Above Upper BB Strength -1.56%
Mar 21 Upper Bollinger Band Touch Strength -1.56%
Mar 20 180 Bullish Setup Bullish Swing Setup -5.00%
Mar 20 Volume Surge Other -5.00%

Older signals for CYCC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Serious Diseases Autoimmune And Inflammatory Diseases Cyclacel Treatment Of Autoimmune And Inflammatory Diseases Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Cell Cycle Checkpoint Cyclin Dependent Kinase Cyclin Dependent Kinase 2 E Human Cancers M Checkpoint Sapacitabine Seliciclib
Is CYCC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.87
52 Week Low 0.51
Average Volume 617,546
200-Day Moving Average 1.168
50-Day Moving Average 0.8088
20-Day Moving Average 0.852
10-Day Moving Average 0.8769
Average True Range 0.0793
ADX 42.17
+DI 31.6212
-DI 5.8314
Chandelier Exit (Long, 3 ATRs ) 0.8121
Chandelier Exit (Short, 3 ATRs ) 0.9879
Upper Bollinger Band 0.9701
Lower Bollinger Band 0.7339
Percent B (%b) 0.91
BandWidth 27.723005
MACD Line 0.0353
MACD Signal Line 0.0215
MACD Histogram 0.0138
Fundamentals Value
Market Cap 10.83 Million
Num Shares 11.4 Million
EPS -4.18
Price-to-Earnings (P/E) Ratio -0.23
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.06
Resistance 3 (R3) 1.06 1.03 1.04
Resistance 2 (R2) 1.03 1.00 1.03 1.03
Resistance 1 (R1) 0.99 0.99 0.98 0.99 1.03
Pivot Point 0.96 0.96 0.95 0.96 0.96
Support 1 (S1) 0.92 0.93 0.91 0.92 0.87
Support 2 (S2) 0.89 0.92 0.89 0.87
Support 3 (S3) 0.85 0.89 0.86
Support 4 (S4) 0.85